What counts as 'modern' in health insurance: who decides?

In an Ombudsman ruling, my claim for Bevacizumab (on the market since 2017) was limited to 25% under the policy's 'modern treatment' coverage. How is 'modern' defined, and is there a timeframe to determine it? Should any treatment available for this long be classified as 'modern'? Please provide detailed criteria or references. -Name withheld on request

- Shilpa Arora

Bevacizumab stands as a beacon of hope for countless patients fighting cancer, offering not just a treatment but a renewed sense of possibility during some of life's challenging moments. As a monoclonal antibody that targets vascular endothelial growth factor, it disrupts the blood supply that tumors need to grow and spread, thereby offering a critical line of defense in the battle against metastatic colorectal cancer and non-squamous non-small cell lung cancer.